[Short-term efficacy and safety of Brolucizumab for neovascular age-related macular degeneration in the Russian Federation].
Alexei N KulikovI R GazizovaDmitrii S MaltsevA Yu MalafeevaA S VasilyevV R ZhalimovaPublished in: Vestnik oftalmologii (2022)
Both treatment-naive nAMD patients and those with the disease remaining active despite anti-VEGF therapy showed a significant decrease in disease activity. In this short-term study, the cumulative risk of intraocular inflammation associated with brolucizumab therapy amounted to 0.65%.
Keyphrases
- age related macular degeneration
- disease activity
- rheumatoid arthritis
- end stage renal disease
- systemic lupus erythematosus
- ejection fraction
- rheumatoid arthritis patients
- chronic kidney disease
- newly diagnosed
- ankylosing spondylitis
- oxidative stress
- peritoneal dialysis
- vascular endothelial growth factor
- juvenile idiopathic arthritis
- stem cells
- hiv infected
- mesenchymal stem cells
- patient reported outcomes
- replacement therapy
- cell therapy
- smoking cessation
- antiretroviral therapy